Lannett Prepares For Insulin Glargine Trial
Pivotal Clinical Trial For Biosimilar Lantus Rival Expected To Begin In March 2022
Executive Summary
Lannett says it is ready to kick off the pivotal clinical trial for the biosimilar insulin glargine candidate it is developing with HEC, after the US FDA completed the safety review of the product’s investigational new drug application.
You may also be interested in...
Lannett: Pricing Pressure ‘Intensified Beyond Historical Norms’
Not many firms report a negative EBITDA when adjusted for costs, but this Lannett's fate during its FY2022 Q2. Management addressed challenges for Lannett’s base business and the ways in which it intends to turn the tide in the coming years.
Lannett: Pricing Pressure Has ‘Intensified Beyond Historical Norms’
Not many firms report a negative EBITDA when adjusted for costs, but this was the fate of Lannett during its financial Q2. Management addressed the challenges for Lannett’s base business and the ways in which the firm intends to turn the tide in the coming years.
Will Eli Lilly’s Rezvoglar Be Able To Compete With Interchangeable Semglee?
The FDA has approved the second biosimilar insulin glargine rival to Lantus, in the form of Eli Lilly’s Rezvoglar. However, Viatris’ recently relaunched Semglee version has an interchangeability designation on its side.